EPCAM_CHICK EPCAM ELISA tesk kit
- Known as:
- EPCAM_CHICK EPCAM Enzyme-linked immunosorbent assay test tesk reagent
- Catalog number:
- gen16460
- Product Quantity:
- 1
- Category:
- Peptides
- Supplier:
- Other suppliers
- Gene target:
- EPCAM_CHICK EPCAM ELISA tesk kit
Related genes to: EPCAM_CHICK EPCAM ELISA tesk kit
- Gene:
- EPCAM NIH gene
- Name:
- epithelial cell adhesion molecule
- Previous symbol:
- M4S1, MIC18, TACSTD1
- Synonyms:
- Ly74, TROP1, GA733-2, EGP34, EGP40, EGP-2, KSA, CD326, Ep-CAM, HEA125, KS1/4, MK-1, MH99, MOC31, 323/A3, 17-1A, TACST-1, CO-17A, ESA
- Chromosome:
- 2p21
- Locus Type:
- gene with protein product
- Date approved:
- 1995-10-02
- Date modifiied:
- 2019-04-23
Related products to: EPCAM_CHICK EPCAM ELISA tesk kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: EPCAM_CHICK EPCAM ELISA tesk kit
- Patients with hormone receptor-positive (HR+) breast cancer faces a persistent, constant risk of distant recurrence for over 20 years. This proof-of-concept study evaluated the clinical utility of circulating tumor cell (CTCs) monitoring using the GenoCTC platform to detect molecular precursors of late recurrence in long-term breast cancer survivors. - Source: PubMed
Publication date: 2026/07/31
Chelakkot ChaithanyaChelakkot Vipin ShankarShin HyehyungCho ChaeyeolPark JieunChoi JiuHong DayeongLee Hun SeokShin Young Kee - Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a five-year survival of approximately 6% that is largely driven by cancer stem cells (CSCs), which promote resistance, metastasis, and recurrence. Mutations in the Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-RAS) are common in human PDAC and activate the rat sarcoma (RAS) pathway, thus supporting tumour growth, maintenance, and metastasis. Newcastle Disease Virus (NDV) is a tumour-selective oncolytic virus with a strong safety profile that targets cancer cells and therapy-resistant CSCs, thereby highlighting its potential as an anticancer virotherapy. This study examines NDV AF2240's ability to target CSCs through RAS pathway modulation and apoptosis induction. - Source: PubMed
Publication date: 2026/02/28
Ghasemi Seyed AbbasLing King-HwaIsmail SailaChau De-MingSekawi Zamberi - Small extracellular vesicles (sEVs) carry biomolecules that reflect their cellular origin, making them attractive biomarkers for breast cancer assessment and human epidermal growth factor receptor 2 (HER2)-status discrimination. However, existing methods involve lengthy isolation procedures and exhibit poor detection performance due to severe interference from excessive impurities. In this study, we constructed a dual-target electrochemical (EC) sensing platform based on cascade aggregation effects. Combined with a facile filter-based isolation strategy, this enables rapid and convenient dual-marker (epithelial cell adhesion molecule (EpCAM) and HER2) analysis of breast cancer-derived sEVs. This mechanism relies on the target-triggered disassembly of DNA nanospheres to release Ag/Hg for EC signaling. Subsequently, colistin specifically binds to G-quadruplexes on unreacted nanospheres and induces their aggregation, sequestering background signal sources and preventing ion leakage. This noise-silencing strategy improved matrix tolerance and reduced background leakage under a standardized diluted-plasma workflow, enabling reliable detection of sEVs-associated signals in filtration-derived clinical samples. A proof-of-concept clinical study involving 63 breast cancer patients and 22 nonmalignant controls successfully demonstrated the platform's capability to distinguish cancer patients from controls. Furthermore, the platform achieved a 88.9% accuracy in differentiating HER2 status within this cohort. Overall, this streamlined "filtration-to-detection" platform offers a promising strategy for analyzing breast cancer-specific sEVs signals and conducting exploratory HER2-status assessments. - Source: PubMed
Publication date: 2026/08/14
Zhang ZhihaoLiu ZijingMeng XiangyueJiang PengjunQu JieJiang YuQiu BinxuChen JieChen Piaopiao - To compare the spatiotemporal localization of Activated leukocyte cell adhesion molecule (Alcam; CD166) and Osterix (OSX), encoded by Sp7, an established odontoblast differentiation marker, during rat molar development using immunohistochemical approaches. - Source: PubMed
Publication date: 2026/08/09
Shibui ToruHosoya AkihiroTakahashi MasamiShibata ShunichiSeki-Kishimoto YuriTakebe HiroakiIrie Kazuharu - Lynch syndrome (LS) is the most common hereditary colorectal cancer (CRC) syndrome, caused by germline pathogenic or likely pathogenic variants (PV/LPV) in mismatch repair (MMR) genes. Data on the spectrum of LS-associated variants in Slavic populations, including Serbia, remain limited. Given the high burden of CRC and endometrial cancer and the limited implementation of hereditary CRC screening, characterizing the spectrum of germline variants in clinically selected high-risk individuals is important for improving genetic testing strategies, risk assessment, and clinical management. Between 2018 and 2025, 176 individuals underwent germline testing for hereditary CRC syndrome based on the Amsterdam/Bethesda criteria, validated LS risk prediction models, and/or family history (FH). Next-generation sequencing (NGS) was performed using the Illumina TruSight Hereditary Cancer Panel, and variants were classified according to American College of Medical Genetics and Genomics and Association for Molecular Pathology (ACMG/AMP) guidelines. PV/LPVs in MMR genes were identified in 27/176 (15.3%) and were associated with positive FH of LS-related tumors ( = 0.0001). Most PV/LPVs were identified in (10.2%), followed by (4.0%) and (1.1%), with no PV/LPVs identified in . Additionally, no pathogenic sequence-level variants detectable by the applied panel-based NGS approach were identified. Recurrent variants were observed in multiple families, and two previously unreported variants were identified. This first systematic analysis of a clinically selected high-risk Serbian cohort provides novel data on the spectrum of LS-associated variants in this referral population, demonstrates the predominance of variants, and supports broader implementation of genetic testing, tumor screening, and genetic counseling. - Source: PubMed
Publication date: 2026/07/25
Djordjic Crnogorac MarijaKaradzic ValentinaCato TeodoraCavic MilenaNikolic NedaSpasic JelenaDjordjevic FedjaJokic VladimirKocic MilanDjurasinovic MiroslavKukic BiljanaNikolic SrdjanRistic MarijaMilovic MarijanaKrivokuca Ana